GlassScriptPhysician profile
Kara Zabelny
NPI 1962897876
$1,839.43
in general payments reported to CMS, 2019-2025
23 companies · $1,105 in 2025
The $1,105 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $254 · 2024: $481 · 2025: $1,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,749 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,749.44 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $343.11 | 2023-2025 | Breztri, Fasenra |
| Insmed, INC. | $211.99 | 2023-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $194.33 | 2024-2025 | |
| Amgen INC. | $138.61 | 2024-2025 | Tezspire, Tavneos |
| Merck Sharp & Dohme LLC | $116.63 | 2023-2025 | Zerbaxa, Dificid, Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.73 | 2023-2025 | Ofev |
| United Therapeutics Corporation | $92.31 | 2023-2025 | Tyvaso, Tyvaso, Orenitram |
| Abbvie INC. | $90.95 | 2023-2024 | Avycaz |
| Takeda Pharmaceuticals U.S.A., INC. | $75.11 | 2024-2025 | Glassia |
| Regeneron Healthcare Solutions, INC. | $70.08 | 2024-2025 | Dupixent |
| Electromed, INC. | $55.87 | 2025 | Smartvest |
| Glaxosmithkline, LLC. | $52.71 | 2025 | Nucala, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $44.85 | 2025 | |
| Philips North America LLC | $43.78 | 2024-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Pfizer INC. | $39.95 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $27.86 | 2025 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $24.38 | 2025 | Opsumit |
| Avadel Cns Pharmaceuticals, LLC | $23.73 | 2025 | Lumryz |
| Inogen, INC. | $20.68 | 2025 | |
| Jazz Pharmaceuticals INC. | $18.85 | 2025 | |
| La Jolla Pharmaceutical Company | $17.22 | 2024 | Giapreza |
| Grifols USA, LLC | $14.86 | 2024 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $14.84 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Zabelny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.